Overview

ARQ 197 in Subjects With Metastatic Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)